II期临床-话题@MedSci

#II期临床#

478篇内容 | 2574人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524846, encodeId=9b941524846b1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, objectType=article, longId=198352, objectId=6b7c198352b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7c198352b0, replyNumber=0, likeNumber=59, createdTime=2020-07-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7c198352b0, moduleTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7c198352b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524845, encodeId=016d152484514, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, objectType=article, longId=198327, objectId=861219832eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861219832eff, replyNumber=0, likeNumber=65, createdTime=2020-07-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861219832eff, moduleTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861219832eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524844, encodeId=5a24152484412, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, objectType=article, longId=198325, objectId=726b198325ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=726b198325ff, replyNumber=0, likeNumber=52, createdTime=2020-07-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=726b198325ff, moduleTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=726b198325ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524843, encodeId=9d5e1524843d7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, objectType=article, longId=198290, objectId=25df198290b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25df198290b5, replyNumber=0, likeNumber=79, createdTime=2020-07-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25df198290b5, moduleTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25df198290b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524847, encodeId=1149152484ee6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, objectType=article, longId=198193, objectId=ccfa198193ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccfa198193ff, replyNumber=0, likeNumber=67, createdTime=2020-07-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccfa198193ff, moduleTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccfa198193ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524842, encodeId=89401524842a9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, objectType=article, longId=198175, objectId=65311981e586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65311981e586, replyNumber=0, likeNumber=61, createdTime=2020-07-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65311981e586, moduleTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65311981e586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524841, encodeId=afca1524841ec, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, objectType=article, longId=197999, objectId=2c2219e999bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2219e999bb, replyNumber=0, likeNumber=80, createdTime=2020-07-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2219e999bb, moduleTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2219e999bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524840, encodeId=146c1524840e9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, objectType=article, longId=197968, objectId=d9bf19e9686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf19e9686d, replyNumber=0, likeNumber=69, createdTime=2020-07-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf19e9686d, moduleTitle=JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf19e9686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524839, encodeId=c2ca15248393c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：Ad5载体COVID-19疫苗II期临床获得成功, objectType=article, longId=197965, objectId=961319e965b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961319e965b0, replyNumber=0, likeNumber=54, createdTime=2020-07-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961319e965b0, moduleTitle=Lancet：Ad5载体COVID-19疫苗II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961319e965b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524838, encodeId=539215248384e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, objectType=article, longId=197879, objectId=2bb519e879bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb519e879bc, replyNumber=0, likeNumber=72, createdTime=2020-07-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb519e879bc, moduleTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb519e879bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524837, encodeId=7c1c152483ea8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=12, createdTime=2020-07-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524836, encodeId=54b7152483601, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=99, createdTime=2020-07-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524835, encodeId=b95515248354e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, objectType=article, longId=197608, objectId=a82f19e608e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f19e608e8, replyNumber=0, likeNumber=11, createdTime=2020-07-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f19e608e8, moduleTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f19e608e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524834, encodeId=77aa1524834f7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：鲁索利替尼治疗白癜风II期临床获得成功, objectType=article, longId=197374, objectId=022919e37410, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022919e37410, replyNumber=0, likeNumber=51, createdTime=2020-07-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022919e37410, moduleTitle=Lancet：鲁索利替尼治疗白癜风II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022919e37410)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524833, encodeId=0b1315248331d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, objectType=article, longId=197270, objectId=3bb219e27057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bb219e27057, replyNumber=0, likeNumber=56, createdTime=2020-07-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bb219e27057, moduleTitle=ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bb219e27057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524832, encodeId=7054152483266, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, objectType=article, longId=196982, objectId=867e19698235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867e19698235, replyNumber=0, likeNumber=0, createdTime=2020-07-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867e19698235, moduleTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867e19698235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524831, encodeId=86c81524831d1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=44, createdTime=2020-07-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524830, encodeId=77a41524830c0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, objectType=article, longId=196772, objectId=914c196e721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914c196e721f, replyNumber=0, likeNumber=61, createdTime=2020-07-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914c196e721f, moduleTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914c196e721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524829, encodeId=47a81524829d8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, objectType=article, longId=196771, objectId=6ae3196e71e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae3196e71e3, replyNumber=0, likeNumber=13, createdTime=2020-07-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae3196e71e3, moduleTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae3196e71e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524828, encodeId=081e15248286a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, objectType=article, longId=196488, objectId=a16319648829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16319648829, replyNumber=0, likeNumber=92, createdTime=2020-06-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16319648829, moduleTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16319648829)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床

2020-07-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行

2020-07-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验

2020-07-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功

2020-07-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

COVID-19疫苗BNT162b2进入II / III期临床研究

2020-07-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组

2020-07-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败

2020-07-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAK抑制剂Rinvoq治疗特应性皮炎：III期临床疗效显著

2020-07-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：Ad5载体COVID-19疫苗II期临床获得成功

2020-07-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功

2020-07-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2020-07-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究

2020-07-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：鲁索利替尼治疗白癜风II期临床获得成功

2020-07-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验

2020-07-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败

2020-07-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2020-07-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功

2020-07-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著

2020-07-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点

2020-06-27

科室
- - 订阅+
  - 更多科室
工具
服务